Oil prices rise on talk of Russia sanctions; bouncing off recent lows
Investing.com - Clear Street raised its price target on BioNTech (NASDAQ:BNTX) to $185.00 from $181.00 on Monday, while maintaining a Buy rating on the stock. The new target aligns with the broader analyst consensus, as InvestingPro data shows analyst targets ranging from $112.20 to $172.05, with a strong Buy recommendation rating of 1.62.
The price target increase follows BioNTech’s second-quarter 2025 results, which showed revenues of €261 million compared to consensus estimates of €151 million. The company’s shares traded up approximately 3% following the earnings release. According to InvestingPro analysis, BioNTech maintains a strong financial position with more cash than debt and an impressive current ratio of 10.18, indicating robust liquidity. Get access to BioNTech’s comprehensive Pro Research Report, part of our analysis covering 1,400+ top US stocks.
BioNTech maintained its full-year guidance, projecting revenues of €1.7-2.2 billion, R&D expenses of €2.6-2.8 billion, SG&A expenses of €650-750 million, and capital expenditures for operating activities of €250-350 million.
Clear Street noted that BioNTech remains on track to report Phase 2 dose optimization results from its BNT327 studies in small cell lung cancer and triple negative breast cancer in the second half of 2025.
The firm cited an improved exchange rate on BioNTech’s Euro-denominated cash balance as a factor in the price target increase, partially offset by dilution related to the Curevac acquisition, and identified BioNTech as its top pick for the second half of 2025.
In other recent news, BioNTech reported a significant increase in its second-quarter 2025 revenue, doubling year-over-year to €260.8 million. This figure notably surpassed analyst estimates, which were set at €137.9 million. Despite the revenue growth, BioNTech posted a net loss of €386.6 million, translating to a loss of €1.60 per share. This was slightly worse than the anticipated loss of €1.41 per share. The company’s financial outlook was further strengthened by a deal with Bristol Myers (NYSE:BMY). These developments have been notable in recent updates about the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.